As Covid-19 cases, including the new JN.1 variant, rise in India, Pune-based Serum Institute of India is gearing up to sell vaccines targeting this variant. The institute, led by Adar Poonawalla, plans to apply for licensing for a vaccine that is “very similar” to the JN.1 variant. Currently, Serum Institute offers a vaccine for the XBB1 variant, and the company aims to obtain licensure for the JN.1 variant in the coming months. The move comes amid a spike in Covid-19 cases, with India reporting 640 fresh infections on Friday and a total of 2,997 active cases.
Serum Institute Readies Vaccine Against JN.1 Variant as Cases Surge
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2023/12/22172656/1683122654-0391.jpg)